Fortis Healthcare Limited (FORTIS) breaks below support, falling 5% today. This decline follows the recent concall for Q1FY27, where the company reported a 17.5% increase in consolidated revenue but also highlighted a slight decrease in EBITDA margins and an increase in net debt. The stock’s move today appears to be a reaction to these mixed signals, coupled with the breakdown below the 6M support trendline. Fortis operates in the healthcare sector, specifically medical care facilities, and today’s move seems to be more company-specific rather than a sector-wide trend.

Technical setup — trendlines & DMA

From a technical standpoint, Fortis Healthcare is currently trading below its 6M support trendline, which ended at ₹937.88, indicating a breakdown. The stock is now 5.83% below this support level and 9.17% below the resistance trendline at ₹967.56. The 50-DMA stands at ₹958.6, and the 200-DMA is at ₹914.4, with the stock currently trading just above the 200-DMA but below the 50-DMA, suggesting a recovery mode. In terms of its 52W range, the stock is in the middle third, 35% up from the 52W low and 19.7% down from the 52W high, indicating that there is still room for both upward and downward movement.

Fundamentals & business context

On the fundamental front, Fortis Healthcare’s PE of 68.7, coupled with an 11.0% profit margin and a revenue CAGR of 13.3%, suggests that the stock is trading at a premium relative to its current earnings. The 21.0% profit CAGR over 5 years indicates strong growth, but the high PE ratio may reflect investor expectations of continued growth. With 47.9% institutional ownership, it appears that institutional investors have a significant stake in the company, which could indicate confidence in its long-term prospects. There was no specific NSE catalyst today, but the recent concall data provides context for the stock’s performance.

Algorithmic scorecard

The algorithmic scorecard for Fortis Healthcare reflects a balanced view, with strengths and weaknesses across both fundamental and technical metrics. One of the strongest signals is the consistent revenue growth every year, indicating exceptional business stability. Another strong point is the very low debt level, with a D/E ratio of 0.00, showcasing excellent financial health. On the weaker side, the stock is considered overvalued with a PEG of 3.27, suggesting it is expensive relative to its growth rate. Additionally, the negligible dividend yield of 0.11% offers little to no income for investors. These factors together paint a picture of a company with solid growth and financial health but at a premium valuation that may not align with its current earnings.

Company outlook

Fortis Healthcare’s recent concall for Q1FY27 revealed several strengths and weaknesses. On the positive side, the company reported a 17.5% increase in consolidated revenue and a 15.8% increase in consolidated operating EBITDA pre-ESOP expenses. The diagnostic business showed an improved operating EBITDA margin. However, the company also faced challenges such as a decrease in consolidated operating EBITDA margin and an increase in net debt. Hospital occupancy remained steady, and margin expansion in certain facilities is expected to take time. These mixed results provide a nuanced view of the company’s current performance.

Looking ahead, Fortis Healthcare’s management has outlined several key initiatives and targets. They are maintaining guidance for a 25% EBITDA margin after running the ESOP cost and expect an improvement in EBITDA margin by 100 basis points at the consolidated level for FY ’27. Revenue growth is expected to be around 12%-13%, with an EBITDA margin in the range of 24%-25% for the diagnostic business. The company is focusing on improving occupancy and EBITDA margins in key facilities such as Manesar and Greater Noida, with an expectation of reaching mid-teens EBITDA margins by the year-end. Additionally, plans to operationalize another 400 beds in the remaining 3 quarters of the year, with a major contribution from the flagship hospital, FMRI, are on track.

Get all details on FORTIS — P&L, peers, shareholding and more on TradeAlone.

Fortis Healthcare Limited (FORTIS) neared resistance today, gaining +5% to ₹967.35 on the NSE, driven by the release of its Q1 FY27 results which showed a 17.5% year-on-year increase in revenue and an Operating EBITDA margin of 22.3%. This move is company-specific, as the stock tests resistance at ₹968, just 0.0% away, after bouncing from support at ₹938. The healthcare sector, particularly medical care facilities, has seen mixed performance, making Fortis’s move noteworthy.

Technical setup — trendlines & DMA

From a technical perspective, Fortis Healthcare is currently testing the 6-month resistance trendline at ₹968, with today’s price just 0.02% below this level. The stock has rebounded from the 6-month support trendline at ₹937.95, which is 3.04% below the current price. The 50-day moving average (DMA) at ₹960.0 is above the 200-DMA at ₹917.1, indicating a bullish trend, though the stock is currently in recovery mode as it trades above the 200-DMA but below the 50-DMA. In the 52-week range of ₹766.8 to ₹1104.3, the current price is in the middle third, suggesting that a significant portion of the potential move may already be priced in.

Fundamentals & business context

Fundamentally, Fortis Healthcare’s PE of 66.8, coupled with profit margins of 11.4% and a revenue CAGR of 13.3%, suggests that the market may be pricing in future growth rather than current earnings. The company’s 47.9% institutional ownership indicates a level of confidence from sophisticated investors, though the absence of a specific NSE catalyst today means the move is likely driven by the strong Q1 results and the approaching resistance level.

Algorithmic scorecard

The overall algorithmic scorecard for Fortis Healthcare reflects a balanced view, with a strong fundamental score and a weaker technical score. The strongest signals include the company’s excellent revenue CAGR of 21.0% and very low debt levels with a D/E ratio of 0.27, indicating robust growth and financial health. On the weaker side, the stock’s overvalued status with a PEG of 3.18 and negligible dividend yield of 0.11% pose risks. These factors suggest that while the company is growing strongly, its valuation may be stretched, and income-seeking investors may find limited appeal.

Company outlook

Fortis Healthcare’s management has outlined an optimistic outlook for the current financial year, expecting 15% plus revenue growth and an additional 150 basis point margin improvement for the hospital business. The diagnostics business is projected to maintain EBITDA margins around 23% to 24%. The company plans to add 1,800 beds over the next four years through brownfield expansion, with an initial target of opening around 100 beds in a new tower at FMRI. Capex is expected to be around INR 900 crores annually, with a focus on both maintenance and growth capex. These initiatives aim to drive double-digit revenue growth, with 70% coming from volume and 30% from value.

Get all details on FORTIS — P&L, peers, shareholding and more on TradeAlone.

Fortis Healthcare Limited (FORTIS) today announced its unaudited consolidated financial results for the quarter ended June 30, 2026. The company reported consolidated revenues of INR 2,545 Cr, up 17.5% year-on-year, and an Operating EBITDA margin of 22.3%. The hospital business revenues stood at INR 2,187 Cr, up 19.0% year-on-year, with an Operating EBITDA margin of 21.5%. The diagnostics business revenues grew by 10.2% to INR 407 Cr, with an Operating EBITDA margin of 23.9%.

Hospital Business Performance

The hospital business revenue growth was driven by a moderate increase in ARPOB and an increase of 16.7% in occupied beds compared to Q1 FY26. The performance for the quarter included recent acquisitions in Punjab, Bengaluru, and a leased facility in Delhi NCR. Excluding the impact of these facilities, on a like-for-like basis, Operating EBITDA margins were similar to Q1 FY26 at 22%.

Diagnostics Business Growth

The diagnostics business continued its network expansion strategy, adding new customer touch points (CTPs) to reach a total of 4,493 as of June 30, 2026. Agilus conducted ~10.46 Mn tests in Q1 FY27, up from ~10.13 Mn tests in Q1 FY26. The preventive and specialized portfolio revenues in Agilus’ overall revenues grew 27% and 13% respectively in Q1 FY27 compared to the corresponding period of the previous year.

Forward-Looking Statement

Commenting on the results, Dr. Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare stated, “Building on the momentum of the previous year, we have made a positive start to the financial year, delivering a steady Q1 performance across both our hospital and diagnostics businesses. We recently entered into an O&M agreement for a 300-bedded greenfield multi-specialty hospital to be developed in Cuttack. This marks Fortis Healthcare’s entry into Odisha, further expanding our presence in growth markets. Our recent acquisitions in our focus geographies are ramping up well. We also continued to invest in our medical infrastructure by expanding our robotic systems across key facilities, reinforcing our commitment to clinical excellence and technology-led care.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Fortis Healthcare Limited

Fortis Healthcare Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Fortis moves sideways over three months, with neither buyers nor sellers taking control. The PEG reaches 3.18. The stock trades on brand and index weight, not on growth. Revenue grows at 13.3% and profits at 21.0% CAGR. The market consistently rewards this kind of compounding. The stock holds at 45% of its 52-week range with RSI at 36. In other words, neither side has a clear edge right now. Revenue grows at 13.3% and profits at 21.0% CAGR — a genuinely strong business. Nevertheless, the stock drops 3.4% in three months. The market sells the stock, not the story. Watch whether that changes at the next earnings. Check Fundamentals of Fortis Healthcare Limited.